全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

日间病房模式下炎症性肠病患者输注生物制剂的效果评价
Evaluation of the Efficacy of Biologics Infusion in Patients with Inflammatory Bowel Disease under Daytime Ward Mode

DOI: 10.12677/ns.2024.139176, PP. 1244-1248

Keywords: 日间病房模式,炎症性肠病,生物制剂,护理模式
Daytime Ward Mode
, Inflammatory Bowel Disease, Biologics Infusion, Nursing Model

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的:评价基于日间病房模式下炎症性肠病患者输注生物制剂的应用效果。方法:选取2023年1月~6月100例炎症性肠病住院患者设为对照组,采用常规护理管理模式。2023年7月~12月105例门诊患者设为观察组,采用日间病房模式。比较两组患者的平均住院费用、平均治疗时间及满意度。结果:两组患者在年龄、性别、文化程度、疾病诊断差异无统计学意义(P > 0.05)。观察组患者治疗时间短于对照组,医疗费用低于对照组,满意度评分高于对照组,差异有统计学意义(P < 0.05)。结论:日间病房模式下,门诊炎症性肠病患者使用生物制剂的输注管理模式的建立缩短患者治疗时间,减轻患者经济负担,提高工作效率及质量,提高患者就医满意度,提高医院经济效益和社会效益。
Objective: This paper aims to evaluate the application effect of biologics infusion in patients with inflammatory bowel disease based on the day ward model. Method: 100 hospitalized patients with inflammatory bowel disease from January to June 2023 were selected as the control group, and conventional nursing management mode was adopted. From July to December 2023, 105 outpatient patients were selected as the observation group and treated in a day ward mode. The average hospitalization costs, average treatment time, and satisfaction between two groups of patients were compared. Results: There was no statistically significant difference in age, gender, educational level, and disease diagnosis between the two groups of patients (P > 0.05). The treatment time of the observation group patients was shorter than that of the control group, the medical expenses were lower than those of the control group, and the satisfaction score was higher than that of the control group, with statistical significance (P < 0.05). Conclusion: Under the daytime ward mode, the establishment of a biologics infusion management model for outpatient inflammatory bowel disease patients can shorten the treatment time, reduce the economic burden on patients, improve work efficiency and quality, enhance patient satisfaction, and improve the economic and social benefits of the hospital.

References

[1]  Baumgart, D.C. and Le Berre, C. (2021) Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. The New England Journal of Medicine, 385, 1302-1315.
https://doi.org/10.1056/NEJMra1907607
[2]  Kaplan, G.G. (2015) The Global Burden of IBD: From 2015 to 2025. Nature Reviews Gastroenterology & Hepatology, 12, 720-727.
https://doi.org/10.1038/nrgastro.2015.150
[3]  李学锋, 彭霞, 周明欢. 我国炎症性肠病流行病学研究进展[J]. 现代消化及介入诊疗, 2020, 25(9): 1265-1267.
[4]  中国医药教育协会炎症性肠病专业委员会. 中国炎症性肠病生物制剂治疗专家建议(试行) [J]. 中华消化病与影像杂志, 2021, 11(6): 244.
[5]  王英德. 新型生物制剂在炎症性肠病中的临床应用: 现状与未来[J]. 中国全科医学, 2021, 24(21): 2629-2633.
[6]  贾洪波. 基本医疗保险制度变迁与国民获得感提升[J]. 社会科学辑刊, 2022(3): 39-49.
[7]  王兆娟, 申俊龙, 熊季霞. 价值医疗视角下我国中医日间病房服务模式分析[J]. 南京中医药大学学报(社会科学版), 2023, 24(6): 416-420.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133